Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial

Peer Review reports

Original Submission
16 Jul 2015	Submitted	Original manuscript
28 Jul 2015	Reviewed	Reviewer Report - Christian Ostheimer
31 Jul 2015	Reviewed	Reviewer Report - Zhanwei Wang
1 Sep 2015	Author responded	Author comments - Tetsuya Fujimura
Resubmission - Version 2
1 Sep 2015	Submitted	Manuscript version 2
16 Sep 2015	Reviewed	Reviewer Report - Zhanwei Wang
16 Oct 2015	Author responded	Author comments - Tetsuya Fujimura
Resubmission - Version 3
16 Oct 2015	Submitted	Manuscript version 3
Publishing
26 Oct 2015	Editorially accepted
2 Nov 2015	Article published	10.1186/s12885-015-1871-z

Back to article page